Skip to main content
Top
Published in: Clinical and Translational Oncology 5/2018

01-05-2018 | Research Article

Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly

Authors: R. Clèries, A. Ameijide, R. Marcos-Gragera, L. Pareja, M. Carulla, M.-L. Vilardell, L. Esteban, M. Buxó, J.-A. Espinàs, A. Puigdefàbregas, J. Ribes, A. Izquierdo, J. Galceran, J. M. Borrás

Published in: Clinical and Translational Oncology | Issue 5/2018

Login to get access

Abstract

Background

Developing effective cancer control programmes requires information on the future cancer burden in an ageing population. In our study we predicted the burden of cancer in Catalonia from 2015 to 2025.

Methods

Bayesian age–period–cohort models were used to predict the burden of cancer from 2015 to 2025 using incidence data from the Girona and Tarragona cancer registries and cancer mortality data from the Catalan mortality registry. Using the Bashir–Estève method, we divided the net change in the number of cases between 2015 and 2025 into changes due to population size (S), cancer risk (R) and age (A) distribution.

Results

By 2025, there will be 21,743 new cancer cases in men (40% aged > 74 years) and 17,268 in women (37% aged > 74 years). More than 40% of the new cases will be diagnosed among population aged 74 and older in prostate, colorectal, lung, bladder, pancreatic and stomach cancers in men, and in colorectal, pancreatic and bladder cancers and leukaemia in women. During 2015–2025, the number of new diagnoses will increase by 5.5% in men (A + R + S = 18.1% − 13.3% + 0.7% = 5.5%) and 11.9% in women (A + R + S = 12.4% − 1.1% + 0.6% = 11.9%). Overall cancer mortality rates will continue to decrease during 2015–2025. Lung cancer will be the most lethal cancer among men (N = 2705) and women (N = 1174).

Conclusions

The increase in the number of cancer cases in Catalonia from 2015 to 2025 will mostly affect the elderly, prompting the need for increased collaboration between geriatricians and oncologists.
Appendix
Available only for authorised users
Literature
2.
go back to reference Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer. 1930;2015:1–5. doi:10.1038/bjc.2014.606. Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer. 1930;2015:1–5. doi:10.​1038/​bjc.​2014.​606.
4.
go back to reference Ribes J, Esteban L, Clèries R, Galceran J, Marcos-Gragera R, Gispert R, et al. Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models. Clin Transl Oncol. 2014;16:714–24. doi:10.1007/s12094-013-1140-z.CrossRefPubMed Ribes J, Esteban L, Clèries R, Galceran J, Marcos-Gragera R, Gispert R, et al. Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models. Clin Transl Oncol. 2014;16:714–24. doi:10.​1007/​s12094-013-1140-z.CrossRefPubMed
6.
go back to reference Clèries R, Buxó M, Martínez JM, Espinàs JA, Dyba T, Borràs JM. Contribution of changes in demography and in the risk factors to the predicted pattern of cancer mortality among Spanish women by 2022. Cancer Epidemiol. 2016;40:113–8. doi:10.1016/j.canep.2015.12.002.CrossRefPubMed Clèries R, Buxó M, Martínez JM, Espinàs JA, Dyba T, Borràs JM. Contribution of changes in demography and in the risk factors to the predicted pattern of cancer mortality among Spanish women by 2022. Cancer Epidemiol. 2016;40:113–8. doi:10.​1016/​j.​canep.​2015.​12.​002.CrossRefPubMed
8.
go back to reference Antonio M, Saldaña J, Carmona-Bayonas A, Navarro V, Tebé C, Nadal M, Formiga F, Salazar R, Borràs JM. Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making? Oncologist. 2017;22(8):934–43. doi:10.1634/theoncologist.2016-0462. Antonio M, Saldaña J, Carmona-Bayonas A, Navarro V, Tebé C, Nadal M, Formiga F, Salazar R, Borràs JM. Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making? Oncologist. 2017;22(8):934–43. doi:10.​1634/​theoncologist.​2016-0462.
10.
go back to reference Clèries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;31:978–87. doi:10.1002/sim.4463.CrossRefPubMed Clèries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;31:978–87. doi:10.​1002/​sim.​4463.CrossRefPubMed
13.
go back to reference Bilal U, Fernández E, Beltran P, Navas-acien A, Bolumar F, Franco M. Validation of a method for reconstructing historical rates of smoking prevalence. Am J Epidemiol. 2014;179:15–9. doi:10.1093/aje/kwt224.CrossRefPubMed Bilal U, Fernández E, Beltran P, Navas-acien A, Bolumar F, Franco M. Validation of a method for reconstructing historical rates of smoking prevalence. Am J Epidemiol. 2014;179:15–9. doi:10.​1093/​aje/​kwt224.CrossRefPubMed
14.
go back to reference Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;2015:1–8. doi:10.1093/annonc/mdv001. Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;2015:1–8. doi:10.​1093/​annonc/​mdv001.
18.
go back to reference Rossi PG, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F, et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol. 2015;110:1359–66. doi:10.1038/ajg.2015.240.CrossRef Rossi PG, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F, et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol. 2015;110:1359–66. doi:10.​1038/​ajg.​2015.​240.CrossRef
21.
go back to reference Bilal U, Beltran P, Fernández E, Navas-Ancien A, Bolumar F, Franco M. Gender equality and smoking: a theory-driven approach to smoking gender differences in Spain. Tob Control. 2016;25:295–300. doi:10.1136/tobaccocontrol.CrossRefPubMed Bilal U, Beltran P, Fernández E, Navas-Ancien A, Bolumar F, Franco M. Gender equality and smoking: a theory-driven approach to smoking gender differences in Spain. Tob Control. 2016;25:295–300. doi:10.​1136/​tobaccocontrol.CrossRefPubMed
23.
go back to reference Hashibe M, Brennan P, Chuang S-C, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomark Prev. 2009;18:541–50. doi:10.1158/1055-9965.EPI-08-0347.CrossRef Hashibe M, Brennan P, Chuang S-C, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomark Prev. 2009;18:541–50. doi:10.​1158/​1055-9965.​EPI-08-0347.CrossRef
26.
go back to reference Murta-nascimento C, Schmitz-Dräger BJ, Zeegers J, Schmitz-dräger MP, Steineck G, Kogevinas M, et al. Epidemiology of urinary bladder cancer: from tumor development to patient’ s death. World J Urol. 2007;25:285–95. doi:10.1007/s00345-007-0168-5.CrossRefPubMed Murta-nascimento C, Schmitz-Dräger BJ, Zeegers J, Schmitz-dräger MP, Steineck G, Kogevinas M, et al. Epidemiology of urinary bladder cancer: from tumor development to patient’ s death. World J Urol. 2007;25:285–95. doi:10.​1007/​s00345-007-0168-5.CrossRefPubMed
27.
go back to reference Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case–Control Consortium (Panc4). Ann Oncol. 2012;23:1880–8. doi:10.1093/annonc/mdr541.CrossRefPubMed Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case–Control Consortium (Panc4). Ann Oncol. 2012;23:1880–8. doi:10.​1093/​annonc/​mdr541.CrossRefPubMed
28.
go back to reference Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I, et al. Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol 2010; 21. doi:10.1093/annonc/mdq088. Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I, et al. Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol 2010; 21. doi:10.​1093/​annonc/​mdq088.
30.
Metadata
Title
Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly
Authors
R. Clèries
A. Ameijide
R. Marcos-Gragera
L. Pareja
M. Carulla
M.-L. Vilardell
L. Esteban
M. Buxó
J.-A. Espinàs
A. Puigdefàbregas
J. Ribes
A. Izquierdo
J. Galceran
J. M. Borrás
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 5/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1764-5

Other articles of this Issue 5/2018

Clinical and Translational Oncology 5/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine